Inventiva S.A Cash Flow Conversion Efficiency
Inventiva S.A cash flow conversion efficiency. Based on the latest financial reports, Inventiva S.A (IVA) has a cash flow conversion efficiency ratio of 1.796x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-51.24 Million ≈ $-59.90 Million USD) by net assets (€-28.52 Million ≈ $-33.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Inventiva S.A (2013–2025)
Cash flow conversion efficiency of Inventiva S.A from 2013 to 2025. This chart illustrates how Inventiva S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IVA live share price for real-time trading data and today's change.
Inventiva S.A Cash Flow Conversion Ratio Explained
Inventiva S.A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Inventiva S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inventiva S.A ranked by their cash flow conversion efficiency. Also see Inventiva S.A stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Focused Photonics Hangzhou Inc
SHE:300203
|
0.015x |
|
Tejas Networks Limited
NSE:TEJASNET
|
-0.154x |
|
Guangzhou Hengyun Enterprises Holding Ltd
SHE:000531
|
0.058x |
|
Canadian General Investments Ltd
TO:CGI
|
-0.004x |
|
Zhejiang Zhaofeng Mechanical and Electronic Co Ltd
SHE:300695
|
0.000x |
|
Hangzhou Advance Gearbox Group Co Ltd
SHG:601177
|
0.028x |
|
Railtel Corporation Of India Limited
NSE:RAILTEL
|
-0.095x |
|
Orient International Enterprise Ltd
SHG:600278
|
0.007x |
Annual Cash Flow Conversion Efficiency for Inventiva S.A (2013–2025)
The table below shows the annual cash flow conversion efficiency of Inventiva S.A from 2013 to 2025. Review Inventiva S.A free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-28.52 Million ≈ $-33.35 Million |
€-104.88 Million ≈ $-122.62 Million |
3.677x | +356.39% |
| 2024-12-31 | €-106.65 Million ≈ $-124.68 Million |
€-85.93 Million ≈ $-100.46 Million |
0.806x | -68.38% |
| 2023-12-31 | €-32.03 Million ≈ $-37.45 Million |
€-81.61 Million ≈ $-95.42 Million |
2.548x | +357.90% |
| 2022-12-31 | €45.48 Million ≈ $53.17 Million |
€-44.93 Million ≈ $-52.53 Million |
-0.988x | -84.33% |
| 2021-12-31 | €88.87 Million ≈ $103.89 Million |
€-47.63 Million ≈ $-55.68 Million |
-0.536x | -94.85% |
| 2020-12-31 | €111.21 Million ≈ $130.02 Million |
€-30.59 Million ≈ $-35.76 Million |
-0.275x | +59.92% |
| 2019-12-31 | €41.39 Million ≈ $48.39 Million |
€-28.40 Million ≈ $-33.21 Million |
-0.686x | -23.57% |
| 2018-12-31 | €61.60 Million ≈ $72.01 Million |
€-34.21 Million ≈ $-39.99 Million |
-0.555x | -109.07% |
| 2017-12-31 | €64.01 Million ≈ $74.83 Million |
€-17.00 Million ≈ $-19.88 Million |
-0.266x | +36.15% |
| 2016-12-31 | €35.72 Million ≈ $41.76 Million |
€-14.86 Million ≈ $-17.37 Million |
-0.416x | -27.24% |
| 2015-12-31 | €42.77 Million ≈ $50.00 Million |
€-13.98 Million ≈ $-16.35 Million |
-0.327x | -13.88% |
| 2014-12-31 | €51.51 Million ≈ $60.22 Million |
€-14.79 Million ≈ $-17.29 Million |
-0.287x | -5.83% |
| 2013-12-31 | €59.01 Million ≈ $68.99 Million |
€-16.01 Million ≈ $-18.72 Million |
-0.271x | -- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more